RxDoctor Payments DataLook up a doctor →

Sandra Fahmy, DO

Family Medicine · Old Bridge, NJNPI 1144317439

Payments from drug & device makers

$14,834in general payments, 2019–2025

Across 976 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$3K
  • AstraZeneca$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Lilly USA, LLC$768
  • Boehringer Ingelheim$673
  • plus $6K from 39 others

What the payments were for

  • Food & beverage$14,782100%
  • Education$520%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,834 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$89,300
Medicare patients
228
Services billed
868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide26$46,868
FarxigaDapagliflozin Propanediol27$29,791
JardianceEmpagliflozin19$24,931
EliquisApixaban22$19,381
JanuviaSitagliptin Phosphate11$17,378
XareltoRivaroxaban17$14,268
Bydureon BciseExenatide Microspheres11$10,586
Topiramate ErTopiramate15$8,928
Icosapent Ethyl15$8,524
Arnuity ElliptaFluticasone Furoate11$3,432
Levothyroxine Sodium248$2,984
Atorvastatin Calcium192$2,503
Rosuvastatin Calcium176$2,240
Albuterol Sulfate HfaAlbuterol Sulfate75$1,917
Olmesartan Medoxomil45$1,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$2,549$46,86826 claims
AstraZenecaFarxiga$1,193$29,79127 claims
Boehringer IngelheimJardiance$673$24,93119 claims
PfizerEliquis$534$19,38122 claims
MerckJanuvia$287$17,37811 claims
Johnson & JohnsonXarelto$197$14,26817 claims
GSKArnuity Ellipta$72$3,43211 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$156$2,984248 claims
AbbVieSynthroid$2,764$1,30951 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Old Bridge

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →